CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.

ABSTRACT:

Background

Optimal management of immunosuppression in kidney transplantation requires a delicate balance of efficacy and toxicity. Tacrolimus (TAC) dose requirements are significantly impacted by genetic variation in CYP3A5 polymorphisms, however the impact that genotype has on clinical outcomes in the pediatric kidney transplant population remains unclear.

Methods

We evaluated a retrospective cohort of 98 pediatric kidney transplant recipients. The primary exposure was CYP3A5 genotype, which classified each recipient into the expresser (at least one CYP3A5*1 allele) or non-expresser group (only CYP3A5*3 alleles). The primary outcome was time to achieve a steady therapeutic TAC concentration. Secondary outcomes include incidence of early allograft rejection and calcineurin i

SUBMITTER: Yanik MV 

PROVIDER: S-EPMC8009482 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature